• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长效注射型抗精神病药物的态度:对患者、家属和精神科医生的调查。

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

机构信息

Department of General and Social Psychiatry, Psychiatric University Hospital Zurich, Lenggstrasse 31, 8032 Zurich, Switzerland.

出版信息

Psychiatry Res. 2010 Jan 30;175(1-2):58-62. doi: 10.1016/j.psychres.2008.11.003. Epub 2009 Dec 11.

DOI:10.1016/j.psychres.2008.11.003
PMID:20004980
Abstract

In many countries fewer than 20% of individuals with schizophrenia receive depot antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's objections to depot treatment. This is the first study that directly compares the attitudes to depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire about their attitudes towards depot antipsychotics was completed by 255 participants (83 patients diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, not directly related to the patients). Patients were more negative towards depot injections than psychiatrists and relatives. They particularly fear to be constricted in their autonomy when treated with depot antipsychotics and that injections might be painful. About 67% of all patients in our sample did not receive information about depot antipsychotics from their psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic episode. Psychiatrists use depot antipsychotics in a conservative way, although they attribute positive traits to the method. Patients' negative attitudes might relate to the low level of information. To enhance the use of depot antipsychotics, information practices of psychiatrists should be improved. Patients should be informed about different forms of treatment during early stages of the illness.

摘要

在许多国家,只有不到 20%的精神分裂症患者接受长效抗精神病药物治疗。经常提到的原因是精神科医生、患者和家属反对长效治疗。这是第一项直接比较精神科医生、患者和家属对长效抗精神病药物的态度的研究。255 名参与者(83 名被诊断为精神分裂症的患者、81 名私人执业的精神科医生和 91 名亲属,与患者没有直接关系)完成了一份关于他们对长效抗精神病药物态度的半结构式问卷。与精神科医生和家属相比,患者对长效注射的态度更为消极。他们特别担心在接受长效抗精神病药物治疗时会限制自己的自主权,并且担心注射会很痛苦。在我们的样本中,约 67%的患者没有从精神科医生那里获得长效抗精神病药物的信息。不到 10%的精神科医生在首次出现精神病发作后会提供长效治疗。精神科医生以保守的方式使用长效抗精神病药物,尽管他们认为这种方法有积极的特点。患者的消极态度可能与信息水平低有关。为了增加长效抗精神病药物的使用,应改善精神科医生的信息实践。应在疾病早期向患者告知不同的治疗形式。

相似文献

1
Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.长效注射型抗精神病药物的态度:对患者、家属和精神科医生的调查。
Psychiatry Res. 2010 Jan 30;175(1-2):58-62. doi: 10.1016/j.psychres.2008.11.003. Epub 2009 Dec 11.
2
Using antipsychotic agents in older patients.在老年患者中使用抗精神病药物。
J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4.
3
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?与口服抗精神病药相比,长效抗精神病药需要在多大程度上更有效,才能被开处方?
Eur Neuropsychopharmacol. 2010 Apr;20(4):276-9. doi: 10.1016/j.euroneuro.2010.01.001. Epub 2010 Feb 4.
4
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.专家共识指南系列。优化精神障碍的药物治疗。引言:方法、评论与总结。
J Clin Psychiatry. 2003;64 Suppl 12:5-19.
5
[Treatment adherence in schizophrenia. A comparison between patient's, relative's and psychiatrist's opinions].[精神分裂症的治疗依从性。患者、家属和精神科医生观点的比较]
Actas Esp Psiquiatr. 2006 Nov-Dec;34(6):386-92.
6
Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists.精神分裂症患者是否未得到充分的第二代抗精神病药物治疗?一项关于德国精神科医生处方习惯的试点研究。
Pharmacopsychiatry. 2003 Nov;36(6):309-12. doi: 10.1055/s-2003-45119.
7
Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.长效注射和口服抗精神病药物:患者的偏好与态度并非一回事。
J Psychopharmacol. 2009 Sep;23(7):789-96. doi: 10.1177/0269881108092124. Epub 2008 Jun 26.
8
Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.精神科医生对精神分裂症患者维持用药的态度。
Psychol Med. 2003 Jan;33(1):83-9. doi: 10.1017/s0033291702006797.
9
Antipsychotic depot medication and attitudes of community psychiatric nurses.抗精神病长效针剂药物与社区精神科护士的态度
J Psychiatr Ment Health Nurs. 2005 Apr;12(2):237-44. doi: 10.1111/j.1365-2850.2004.00826.x.
10
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.精神分裂症:患者及专业护理人员对该疾病及抗精神病药物的态度。
Pharmacopsychiatry. 2004 May;37(3):103-9. doi: 10.1055/s-2004-818987.

引用本文的文献

1
Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study.长效注射用抗精神病药物与口服抗精神病药物治疗精神分裂症患者的临床结局:一项自然主义研究。
Healthcare (Basel). 2025 Jul 16;13(14):1709. doi: 10.3390/healthcare13141709.
2
Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan.棕榈酸帕利哌酮长效注射液(PP1M)治疗精神分裂症患者的心血管事件风险:台湾基于人群的回顾性队列研究。
Clin Drug Investig. 2024 May;44(5):329-341. doi: 10.1007/s40261-024-01358-y. Epub 2024 Apr 15.
3
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study.
首发精神分裂症患者口服与长效注射用抗精神病药物的比较:一项为期12周的干预性研究。
Indian J Psychiatry. 2023 Apr;65(4):404-411. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22. Epub 2023 Apr 11.
4
Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.精神分裂症患者对长效注射治疗的态度及其影响因素:基于社区的横断面调查。
Front Public Health. 2022 Oct 10;10:951544. doi: 10.3389/fpubh.2022.951544. eCollection 2022.
5
Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania.罗马尼亚新冠疫情期间长效注射用抗精神病药物(LAIs)的处方趋势
Healthcare (Basel). 2022 Jul 7;10(7):1265. doi: 10.3390/healthcare10071265.
6
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years' experience at a UK high-secure hospital.奥氮平长效注射剂、停药率及停药原因:英国一家高度戒备医院的10年经验
Ther Adv Psychopharmacol. 2022 Jul 18;12:20451253221113093. doi: 10.1177/20451253221113093. eCollection 2022.
7
Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland.瑞士一家学术性精神病医院中长效注射用抗精神病药物在精神分裂症谱系障碍住院患者中的应用
J Pers Med. 2022 Mar 11;12(3):441. doi: 10.3390/jpm12030441.
8
One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives.帕利哌酮棕榈酸酯治疗精神障碍的1个月与3个月剂型:患者、亲属及精神卫生专业人员的观点
Patient Prefer Adherence. 2022 Mar 4;16:615-624. doi: 10.2147/PPA.S349460. eCollection 2022.
9
Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis.抗精神病药物相关的污名化及其对治疗选择的影响:一项系统综述与框架综合分析
Patient Prefer Adherence. 2022 Feb 16;16:373-401. doi: 10.2147/PPA.S343211. eCollection 2022.
10
Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians.长效注射用抗精神病药物治疗精神分裂症:临床医生教育需求评估
Neuropsychiatr Dis Treat. 2022 Jan 26;18:111-123. doi: 10.2147/NDT.S326299. eCollection 2022.